Evaluating the chromatinized erbB2 gene in nuclei from breast cancer cells expressing varying levels of ErbB2 transcripts, we identi®ed a nuclease-sensitive site within a 0.22 kb region of maximum enhancer activity centered over a conserved 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an adjacent essential Ets binding site (EBS). Promoter footprinting with nuclear extracts reveals an intense Ets hypersensitivity site at the EBS whose degree of intensity correlates with the level of cellular ErbB2 expression. In vitro mapping assays show that the supercoiled erbB2 promoter forms an internal triplex structure (Hr-DNA) at the mirror-repeat element. Mutations preventing Hr-DNA formation can enhance erbB2 promoter activity in human breast cancer cells, a result consistent with previous demonstration that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in triplex binding, and new results suggesting that Ets binding induces severe promoter bending that may restrict local triplex formation. In addition to previously described erbB2-regulating breast cancer Ets factors (PEA3, ESX/Elf-3), Elf-1 is now shown to be another endogenously expressed Ets candidate capable of binding to and upregulating the erbB2 promoter. Given current strategies to transcriptionally inhibit ErbB2 overexpression, including development of novel erbB2 promoter-targeted therapeutics, an EBS-targeted approach is presented using chimeric Ets proteins that strongly repress erbB2 promoter activity.
Introduction
Activation of the ErbB2 (HER2/neu) receptor tyrosine kinase as found in human breast and other epithelial cancers results primarily from transcriptional overexpression o episomally and chromosomally ampli®ed copies of the erbB2 oncogene. Following initial characterization of the erbB2 promoter sequence over a decade ago (Ishii et al., 1987; Tal et al., 1987) , there has been renewed interest in understanding erbB2 transcriptional control with increasing appreciation of the clinical successes and limitations of ErbB2 receptortargeted therapy (Benz and Tripathy, 2000; Krauss et al., 2000) . In theory, downregulating erbB2 may be accomplished more eciently and permanently by incapacitating the 2 ± 10-fold ampli®ed copies of this oncogene's promoter rather than targeting a geometrically greater number of erbB2 transcripts or the 10 5 to 10 6 steady-state receptor molecules present on each overexpressing cancer cell. Several anti-transcriptional erbB2 therapeutic strategies are currently under development and at least one such therapeutic agent has entered clinical trials based on its empirically observed repression of erbB2 promoter activity (Chen et al., 1997a; Hung and Wang, 2000) .
Much of our current understanding of erbB2 promoter function rests on human and murine sequence data and transient transfection experiments comparing normal with mutated/deleted erbB2 promoter ± reporter constructs. These previous studies have described positive and negative regulatory elements across the erbB2 promoter (Suen and Hung, 1990; Hudson et al., 1990; Hollywood and Hurst, 1993; Scott et al., 1994; Grooteclaes et al., 1994; Gill, 1994, 1996; Mizuguchi et al., 1994; Bosher et al., 1995 Bosher et al., , 1996 Raziuddin et al., 1997; Chen et al. 1997c) . These reports generally indicate that the most proximal 0.22 kb of promoter, relative to the two major erbB2 transcription initiation sites at +1 and 769 bp, contains the most positive-acting regulatory elements, with the downstream half of this region thought to account for much of the 16 ± 32-fold greater mRNA/ gene copy expression levels seen in ErbB2 overexpressing breast cancer cells relative to low expressing cells (Kraus et al., 1987; Scott et al., 1994) .
Major genomic features including the ®ve dierent positive-acting control elements reported for the erbB2 proximal promoter are shown in Figure 1 . A conserved CCAAT box (from 777 to 773 bp, shown binding NFY) and nonconserved TATAA box (from 728 to 724 bp, not shown in Figure 1 ) present in the human promoter¯ank both a conserved Ets binding site (EBS, the GAGGAA element from 735 to 730 bp) and adjacent 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat. Nuclear extracts from a range of ErbB2 expressing breast cancer lines ®rst demonstrated a proximal promoter footprint overlapping the 5' half of the polypurine-polypyrimidine mirror-repeat (Hollywood and Hurst, 1993) . A single DNase-I hypersensitive chromatin site found centered over the mirrorrepeat and adjacent EBS drew attention to this most proximal promoter region . Both this earlier study and a recent report (Xing et al., 2000) showed that mutation of the EBS severely reduces erbB2 promoter activity, particularly in breast cancer cells that overexpress ErbB2. At least 10 dierent Ets factors have since been found expressed in human breast cancer cells with varying levels of ErbB2 co-expression (GABPa, Elk-1, Ets-2, PEA3, ERM, ER81, NET, Elf-1, ESX/Elf-3, Elf-5). To date, only two Ets family members (PEA3, ESX/Elf-3) have been studied as potential erbB2 transactivators Chang et al., 1997) ; in the present study a third candidate, Elf-1, is also evaluated for its expression in human breast tumors and its ability to bind and transactivate the erbB2 promoter.
The erbB2 promoter's polypurine-polypyrimidine mirror-repeat, which lies immediately upstream of the EBS and within the more recently described matrix attachment region (Raziuddin et al., 1997) , has attracted additional attention as a therapeutic target because of its ability to bind triplex-forming oligonucleotides. Triplex formation at the mirror-repeat element has been shown to prevent Ets protein binding at the EBS and inhibit erbB2 transcription (Ebbinghaus et al., 1993 (Ebbinghaus et al., , 1999 Noonberg et al., 1994; Porumb et al., 1996) . When placed in a supercoiled plasmid, such mirror-repeats readily form endogenous triplex structures known as H-DNA (Mirkin, 1999 ). An increasing body of evidence suggest that H-DNA structures negatively regulate both DNA replication and RNA transcription (Mirkin, 1999) , and may direct subnuclear promoter localization through recruitment of tissue-speci®c H-DNA binding proteins (Guieysse and Praseuth, 1999) . In addition to a controlling role for the erbB2 promoter's mirror-repeat element, tissuespeci®c regulation of this proto-oncogene might derive from the proximal promoter's EBS while development-speci®c regulation might come from the EBS, Notch-activated RBPJk (Chen and Gill, 1996; Chen et al., 1997c) , AP2 (Bosher et al., 1995 (Bosher et al., , 1996 and/or cooperative interactions between the transactivators binding these elements. Given the diverse and critical gene programs controlled by developmentspeci®c and tissue-restricted transcription factors, in particular members of the Ets family (Benz, 1998; Marden and Benz, 2000) , eorts to fully understand the structural and functional regulators of erbB2 promoter activity are necessary not only to better de®ne the earliest erbB2 dysregulating mechanisms associated with oncogene activation and malignant transformation, but also to develop novel and speci®c erbB2 oncogene-targeted cancer therapeutics.
Results
Nuclease-sensitive erbB2 promoter region contains an essential EBS bordering a H-DNA forming element Evaluating up to 2 kb of chromatinized erbB2 promoter by DNase-I treatment of nuclei from breast cancer cells expressing varying levels of ErbB2 mRNA/ gene copy, we found a single hypersensitivity site within the region of known maximum relative enhancer activity centered over the conserved 28 bp polypurine (GGA)-polypyrimidine (TCC) mirror-repeat and adjacent Ets binding site (EBS). The functional relevance of this EBS was shown by mutational analysis to be most pronounced in ErbB2 overexpressing cancer cells , and the relative importance of this EBS was recently con®rmed (Xing et al., 2000) . Since this singular DNase-1 hypersensitive site suggested a localized area of open chromatin associated with transcriptional overexpression, DNase-I footprinting of the erbB2 proximal promoter with nuclear extracts from breast cancer cells was performed. As shown in Figure 2a , a footprint assay using a 125 bp linear fragment from the erbB2 proximal promoter titrated with increasing amounts of a recombinant full-length Ets protein reveals that the ®rst detectable in¯uence of Ets binding is the appearance of the characteristic EBS hypersensitivity site followed by development of a surrounding footprint spanning up to 20 protected bases. Additionally, a full-length recombinant Ets protein (PU.1) protects at least twice the linear promoter length as compared to a truncated recombinant version containing only the conserved Ets DNA binding C-terminal domain, with the full-length Ets showing additional 3' (downstream) footprint extension from the commonly located EBS hypersensitivity site and across the adjacent TATAA box (data not shown). Figure 1 Proximal promoter features regulating erbB2 transcription. Genomic landmarks and known positive-acting regulatory elements (EBS, NFY, R/N*, Sp1, AP2) localized in relationship to the primary site of transcript initiation at +1 bp and a secondary site at 769 bp preferentially upregulated during promoter-driven erbB2 overexpression. Transactivator proteins thought to bind these regulatory elements include Notch-activated RBPJk (R/N*), and members of the Ets (EBS), Sp1 (Sp1), AP2 (AP2) and CCAAT box binding protein (NFY) families. Other known regulatory features include the matrix attachment region (MAR) containing the 28 bp triplex-forming polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an open-chromatin region of DNase-I hypersensitivity (HS) centered over the Ets binding site (EBS) and mirror-repeat element When nuclear extracts of equal protein content (but containing various endogenous Ets factors) derived from breast cancer cell lines of either high (MDA-453, BT-474, ZR-75-1) or low (MCF-7, BT-20, HBL100) ErbB2 expression are footprinted against the same erbB2 promoter probe, two dierent promoter-binding patterns are apparent. The ErbB2 overexpressing cells show a more intense hypersensitive EBS and a localized non-contiguous footprint mapping to the upstream half of the mirror-repeat's non-coding/ template strand (Figure 2b ). In contrast, the low ErbB2 expressing cells show a more weakly hypersensitive EBS and, of the three cell line extracts, a much broader footprint extending 5' from the EBS and beyond the mirror-repeat ( Figure  2c ). Of note, footprinting the complementary (coding/ non-template) promoter strand showed no EBS hypersensitivity site or associated footprint (data not shown). The fact that the EBS hypersensitivity sites seen in these footprinting studies correlate well with the chromatin DNase-I results , in relation to position and signal strength, and scale with cellular ErbB2 transcript levels suggest that both are dependent on Ets factor binding to the EBS. Attributing the chromatin DNase-I hypersensitivity site to Ets factor binding is consistent with the digestion kinetics of chromatin in response to DNase-I since the rate of double stranded DNA cleavage in this assay is determined by ®rst strand cleavage susceptibility. Additionally, the DNase-I footprinting dierences between high and low ErbB2 expressing cells support the likelihood that low ErbB2 expressing cells possess non-Ets factors that bind and regulate this region of the erbB2 proximal promoter.
The triplex-forming capacity of the polypurinepolypyrimidine mirror-repeat immediately upstream of the EBS presents another target of potential nuclease sensitivity. S1 digestion and single strand-speci®c chemical probing of a supercoiled erbB2 promoter construct (RO6) were undertaken to determine if this element could spontaneously adopt the non-B DNA architectural conformation known as H-DNA, with its characteristic single-strand D loop. As illustrated in Figure 3 , a major S1 hypersensitive single strand site is apparent within the *500 bp supercoiled erbB2 promoter sequence and maps to the polypyrimidine tract on the non-coding/template strand of the mirrorrepeat, characteristic of the Hr-DNA isomeric form (Mirkin, 1999) . Up to two much weaker and less eciently cut S1 sites were found within the polypurine coding/non-template strand of the element, suggesting a less favored Hy-DNA isomeric conformation or smaller regions of single-strand structure in the Hr-DNA conformation. As required for all H-DNA Figure 2 DNase-I footprinting of the erbB2 proximal promoter reveals hypersensitivity site (*) within the Ets binding site (EBS) whose intensity correlates with cellular transcription of ErbB2. (a) Footprint assay using a 125 bp linear fragment ( 32 P-labeled on the non-coding strand) from the erbB2 proximal promoter titrated with increasing amounts of a recombinant full-length Ets protein (PU.1), as described in Materials and methods, and showing that the earliest detectable in¯uence of Ets binding is the appearance of characteristic hypersensitive site within the EBS (boxed 3'-CCTT-5' core element), followed by progressive enhancement of a surrounding footprint spanning up to 20 protected bases and overlapping the adjacent TATAA box (3'-ATATT-5'). (b and c) Footprint assay performed as above but using nuclear extracts of equal protein content from breast cancer cell lines of either high (MDA-453, BT-474, ZR-75-1) or low (MCF-7, BT-20, HBL100) ErbB2 expression level and revealing two dierent erbB2 promoterbinding patterns. Control DNase-I footprint assays (c) were performed without addition of recombinant protein or nuclear extract conformations, negative supercoiling is essential for both the S1 site and strand speci®city since no discrete digestion products are detectable with the linearized (Pst1 and/or HindIII restricted) construct; as well, the control plasmid lacking the erbB2 promoter insert reveals no S1 susceptibility. To con®rm and better resolve the single-stranded polypyrimidine tract forming the Hr-DNA D loop of the erbB2 promoter element, chemical probing of the supercoiled construct was performed using osmium tetroxide (OT) and diethylpyrocarbonate (DEPC), which are speci®c for T pyrimidine and A or G purine bases, respectively, that are not involved in either Watson-Crick or Hoogsteen hydrogen bonding. As shown in Figure 4 , a Pst1/BssHII fragment from the probed construct evaluating sequences just upstream of the polypurinepolypyrimidine mirror-repeat shows no speci®c T or purine base susceptibility to chemical probing by either strand. In contrast, the BssHII/BgIII fragment containing the mirror-repeat shows a pattern of T and purine base chemical susceptibility consistent with an isolated polypyrimidine D loop present in Hr-DNA. As another negative control, the non-supercoiled (linearized) form of this same construct showed the expected lack of T or purine base susceptibility to these chemical probes. Figure 4c summarizes the strand speci®city of the chemically susceptible bases and the deduced Hr-DNA structure of the erbB2 promoter's polypurine-polypyrimidine mirror-repeat. Taken together, these results suggest that an Hr-DNA structure in the promoter's mirror-repeat element could contribute to the observed chromatin nuclease sensitivity.
To explore the possibility that this deduced Hr-DNA structure might aect intracellular erbB2 promoter function, an Hr-DNA mutation was introduced into the erbB2 reporter plasmid RO6 by changing the critical ®rst GGA repeat, immediately downstream of the element's central T:A bp, to a non-triplex forming ACC triad. In transient transfection assays in low ErbB2 expressing MCF-7 breast cancer cells, the Hr-DNA mutated RO6 displayed an activity threefold over wild type RO6, consistent with previous reports that H-DNA forming elements produce transcriptional stalling possibly due to formation of stable complexes between the H-DNA D loop and nascent transcript (Mirkin, 1999) .
Ets-induced erbB2 promoter bending
We previously described the inability of a linearized erbB2 promoter probe to bind a recombinant Ets protein at the EBS when the adjacent duplexed mirrorrepeat element was constrained by a triplex-forming oligonucleotide (Noonberg et al., 1994) ; likewise, earlier structural studies had suggested that DNA binding by a minimal *85 amino acid Ets domain could induce DNA bending (*108) as well as other duplex constraints (e.g. minor groove enlargement) which might impair local H-DNA formation in the presence of a bound Ets factor (Kodandapani et al., 1996; Werner et al., 1997) . To better understand the erbB2 promoter binding characteristics of Ets proteins, bending angle assays were performed using truncated and full-length versions of two non-homologous Ets proteins, PU.1 and ESX/Elf-3, both of which bind avidly to the erbB2 promoter's EBS via their conserved Ets DNA binding domains (DBD). Induction of erbB2 promoter bending was measured by an established Figure 3 Strand-speci®c S1 hypersensitivity sites localized in the polypurine(GGA)-polypyrimidine(TCC) mirror-repeat of supercoiled erbB2 proximal promoter. As described in Materials and methods, S1 treated (S1) supercoiled erbB2 promoter plasmid or untreated control plasmid were digested with Pst1 (P) and/or HindIII (H), electrophoresed on a denaturing gel, blotted onto a membrane and hybridized with the single strand probes A (bottom, non-coding and template strand), B and C (top, coding and non-template strand). The polypurine(GGA)-polypyrimidine(TCC) mirror-repeat is represented by bold head-to-head arrows in the Pst1-HindIII map. The^marked autoradiograph band results from a major bottom strand S1 cut site (: on map) combined with HindIII restriction (probe A, S1/H lane). Two minor S1 cut sites (; on map) are identi®ed with probes B and C with Pst1 restriction and displayed here as autoradiographs exposed 10-fold longer than that for probe A (note probe B and C bands marked * and +, S1/P lanes). Uncertainty in exact location of two of the three S1 cut sites is indicated by bottom and top strand horizontal brackets. Localization of the S1 site producing the + band is demonstrated by hybridization with probe C but not with probe B. Controls (P, H and P/H) and S1 treatment alone (S1) produced expected hybridization patterns (note 270 bp band in P/H lane); S1 treatment of linearized plasmid gave a single 5.4 Kbp uncut band (not shown) circular permutation assay which revealed that the degree of bending about the promoter's EBS increases with the size of the bound Ets protein, as demonstrated in Figure 5 . Truncated PU.1 (amino acids 159 ± 272), slightly larger than the Ets domain fragment used to structurally characterize DNA-bound PU.1 by X-ray crystallography (Kodandapani et al., 1996) , produced an electrophoretically calculated promoter bending angle of 228 while full-length PU.1 produced a calculated angle of 658 (data not shown). Similarly, progressive truncations of ESX/Elf-3 which removed more than the ®rst 100 N-terminal amino acids resulted in calculated DNA bending angles signi®cantly reduced from the 808 bending angle produced by full-length ESX/Elf-3 ( Figure 5 ). While the minimal degrees of DNA bending induced by the truncated Ets domains from PU.1 and ESX/Elf-3 are in reasonable accord with the crystallographic results (Kodandapani et al., 1996) , the enhanced bending observed by both of the full-length PU.1 and ESX/Elf-3 proteins is surprising given their lack of homology outside their DNA binding Ets domains, suggesting that the structural motifs responsible for this enhanced eect are protein speci®c. To assure that this enhanced bending eect was not due simply to a dramatic change in Ets protein shape or rigidity (independent of Ets-induced promoter bending), which can cause anomalous results in electrophoretic assays of DNA bending, a ligasemediated DNA cyclization assay was also performed. This non-electrophoretic cyclization assay showed that both full-length PU.1 and ESX/Elf-3 enhanced the rate of ring formation by the 136 bp erbB2 promotercontaining DNA fragment almost 1.5-fold over the linear fragment background rate (data not shown), consistent with that induced by POU s domain-containing transcription factors known to both bend DNA Figure 4 Strand-speci®c chemical probing of supercoiled erbB2 proximal promoter and proposed Hr-DNA conformation within the promoter's mirror-repeat element. Strand-speci®c chemical probing was performed on the same supercoiled promoter construct used in Figure 3 , before 32 P-labeling of either the non-coding/template strand shown in (a) or the coding/non-template strand shown in (b). As described in Materials and methods, probing was performed using osmium tetroxide (OT) or diethylpyrocarbonate (DEPC), which speci®cally modify T pyrimidines and A or G purine bases, respectively, if they are not involved in Watson-Crick or Hoogsteen hydrogen bonding. The Pst1/BssHII) fragment from the probed construct evaluates sequences just upstream of the polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and shows no speci®c T or purine base susceptibility to chemical probing by either strand. In contrast, the BssHII/BgIII fragment contains the mirror-repeat element and shows a pattern of T and purine base chemical susceptibility (in (a), note OT induced bands 1, 2, 3, 4 and 6, and DEPC induced band 5; in (b), note OT induced bands 7 and 8, and no DEPC induced bands) consistent with an isolated polypyrimidine loop in the upstream half of the mirror-repeat and isolated areas of pyrimidine base susceptibility just before and after this element. As a negative control, the non-supercoiled promoter construct (linearized plasmid) shows the expected lack of T or purine base susceptibility to these chemical probes. (c) Summary diagram of the strand-speci®c, chemically susceptible bases and deduced Hr-DNA conformation assumed under supercoil conditions in vitro by the erbB2 promoter's polypurine-polypyrimidine mirror-repeat. The upstream promoter element indicated by the ®lled bar is the CCAAT box and the downstream element indicated by the open bar is the Ets binding site (EBS) and enhance its cyclization when studied by the same assays employed here (Verrijzer et al., 1991) . Structural studies are needed to con®rm the observed severe degree of DNA bending induced by full-length Ets proteins, and would lend additional support to the existing preliminary data suggesting that Ets protein binding to the erbB2 promoter's EBS is incompatible with triplex formation at the upstream mirror-repeat element.
Elf-1 as an erbB2-regulating Ets factor candidate
Among the dierent Ets factors that have been found expressed in human breast cancer cell lines (GABPa, Elk-1, Ets-2, PEA3, ERM, ER81, NET, Elf-1, ESX/ Elf-3, Elf-5), previous studies have focused only on PEA3 and ESX/Elf-3 as potential endogenous transactivators of erbB2 Chang et al., 1999) . Although Elf-1 expression is often thought to be restricted to lymphocytes and lymphocytic lines such as Jurkat and Raji (Bredemeier-Ernst et al., 1997), Figure  6 shows that Elf-1 is widely and variously expressed among dierent human mammary epithelial lines of malignant and non-malignant origin, with some breast cancer cell lines like MCF-7 expressing Elf-1 protein levels comparable to those found in Jurkat and Raji cells. EMSA analyses of nuclear extracts from these breast cancer cell lines show that Elf-1 binds to an erbB2 promoter probe in proportion to its total cellular content ( Figure 6b) ; as well, use of excess (506) unlabeled oligonucleotide competitors bearing mutations in or about the EBS demonstrate that Elf-1 binding to the promoter probe is speci®c for the GGAA core response element within the promoter's EBS (data not shown). When MCF-7 or SK-BR-3 breast cancer cells are co-transfected with a 500 bp (p500) or 300 bp (p300) erbB2 promoter-luciferase construct and an Elf-1 expressing vector, erbB2 promoter activity is increased 1.5-fold in the MCF-7 cells (data not shown) and 15 ± 25-fold in the SK-BR-3 cells as compared to control transfectants ( Figure 6c ). Consistent with the EMSA results, mutating the EBS core element in the promoter ± reporter construct (p 500 m) from GGAA to GAGA largely prevents Elf-1 transactivation of erbB2 (Figure 6c ).
Unlike surveys of breast cancer cell lines and primary breast tumors revealing correlations between ErbB2 overexpression and transcriptional upregulation of PEA3 or ESX/Elf-3 Chang et al., 1999; Benz et al., unpublished) , Elf-1 expression studies reveal no signi®cant correlation with ErbB2 expression status. Northern blots (with expected 3.8 kb transcript band, data not shown) and Western blots (with expected *97 kDa band, Figure 6a ) reveal no signi®cant dierences in Elf-1 expression levels between low (MCF-10A, MCF-7, MDA-231, MDA-468, HBL-100) and high (MCF-7/HER2-18, BT-474, MDA-453, ZR-75-1, SK-BR-3) ErbB2 expressing mammary epithelial cell lines. A semiquantitative immunohistochemical assessment of nuclear Elf-1 expression, validated against Western blotted control cell lines, was performed on 20 paran-archived primary invasive ductal breast tumors of known ErbB2 expression status: three without detectable ErbB2 immunoreactivity, eight with low-intermediate ErbB2 expression, and nine with ErbB2 overexpression. Nuclear Elf-1 expression was detected at some level (median=40% of epithelial cells; range=5 to 100%) in all of the tumor samples, and these levels showed an insigni®cant correlation (70.24 linear regression coecient, P40.1) with ErbB2 expression levels. Reconciling this lack of positive correlation between Elf-1 and ErbB2 expression levels by immunohistochemical detection with the positive correlating EBS hypersensitivity site intensity from the footprint analysis of nuclear extracts (Figure 2 ) leads to alternative explanations: (i) Elf-1, while abundantly and ubiquitously expressed in these breast tumor cells, is capable of binding and transactivating the erbB2 promoter in the described assays but cannot compete with one or more other endogenous Ets factors (e.g. PEA3, ESX/ Elf-3) that account for the promoter footprinting Figure 5 Ets induced erbB2 promoter bending. Induction of erbB2 promoter bending was measured by the circular permutation assay using a 16 bp erbB2 promoter fragment (coding strand: TGCTTGAGGAAGTATA) containing the EBS (GAGGAA) cloned into pBend2 to produce 32 P-labeled and circularly permutated bending probes (BamHI, BgIII and StuI) of 136 bp whose mobility is measured after Ets (ESX/Elf-3) protein binding and gel electrophoresis, as detailed in Materials and methods. The series of N-terminally deleted recombinant ESX/Elf-3 protein fragments (characterized by amino acid residues and molecular weight, M.W.) are diagrammatically shown in relation to the full 371 amino acid (43 kDa) domain-oriented ESX/Elf-3 structure. Bending angles (a) were calculated using the standard equation cos(a/2)=m m /m E , where m m is the gel distance migrated by the protein-bound StuI fragment and m E is the gel distance migrated by the protein-bound BamHI fragment. The smallest ESX/Elf-3 protein fragment (266/355, 12.5 kDa) is unable to bind to the 16 bp EBS-containing promoter probe; unbound probe is referred to as free band results and endogenous promoter upregulation in ErbB2 overexpressing breast cancers; or (ii) at the levels detected in these various cell lines and tumor samples Elf-1 is an essential transactivator of the erbB2 promoter, but the net cellular expression of ErbB2 also depends on other more limiting promoter regulators (as depicted in Figure 1) including the presence of a downregulating H-DNA stabilizing factor whose binding alters the promoter's architecture and footprint pattern (as in Figure 2c ) and precludes both Elf-1 binding and transactivation.
EBS-targeted repression of erbB2 promoter activity
Given the essential nature of the erbB2 promoter's EBS and uncertainty about the exact promoter architecture or Ets family member associated with ErbB2 overexpression, downregulation of erbB2 promoter activity was attempted in ErbB2 overexpressing MDA-453 cells using an EBS-targeted approach. Chimeric Ets constructs containing the KRAB domain (KK4) from KOX1 (amino acids 1 ± 160) fused at the N-terminus of the DNA binding Ets domains from either PEA3 or ESX/Elf-3 were transiently co-transfected along with either pHER2-CAT or pTA5-CAT erbB2 promoter ± reporter constructs. As a positive control for promoter binding speci®city, an AP2 DNA binding domain (DBD) was similarly fused to KK4 and this construct compared for its ability to repress the pHER2-CAT promoter ± reporter, which contains a well-known AP2 promoter response element near the upstream Pst1 site at 7220 bp (Hollywood and Hurst, 1993) , and its eect on the truncated pTA5-CAT promoter ± reporter which lacks any functional AP2 response elements. Negative controls consisted of vector (pCDNA1) alone, the non-DNA binding KK4 expression construct, and KK4 fusion constructs containing reversely oriented Ets and AP2 DBD domains (nonsense expressing sequences). Cells transfected with KK4-expressing constructs were tested by Western blotting with an anti-KK4 polyclonal which detected the 20 kDa KK4 product, 31 kDa KK4-Ets(PEA3-DBD) and KK4-Ets(ESX/Elf-3-DBD) or 45 kDa KK4-AP2(DBD) fusion proteins. As shown in Figure 7 , all negative expression controls produced no signi®cant dierences or impact on pHER2-CAT and pTA5-CAT promoter ± reporter activities. The positive speci®city control construct, KK4-AP2(DBD), decreased pHER2-CAT promoter activity to 54% of control without aecting pTA5-CAT promoter ± reporter activity, as expected. KK4-Ets(DBD) constructs containing either the PEA3-DBD or the ESX/Elf-3-DBD did not result in Figure 6 Elf-1 expression in human breast cancers and its ability to speci®cally bind to and transactivate the erbB2 promoter. (a) Western blot detection of Elf-1 in malignant (MCF-7, MCF-7/HER2-18, MDA-231, MDA-468, BT-474, MDA-453, ZR75-1, SK-BR-3) and non-malignant (MCF-10A, HBL-100) human mammary epithelial cell lines as compared to two transformed lymphocytic cell lines (Jurkat, Raji). Equal quantities (15 mg) of nuclear extract were electrophoresed, membrane transferred and blotted with Elf-1 speci®c antibody. (b) Electrophoretic mobility shift assay (EMSA) performed on the same nuclear extracts shown in (a) and probed with an EBS-containing erbB2 promoter probe (TA5) revealing Elf-1 complexes with the erbB2 promoter probe (arrow) which are supershifted in the presence of co-incubated anti-Elf-1 antibody (asterisk). (c) Transactivation of the erbB2 promoter by Elf-1. SK-BR-3 cells were co-transfected with either EBS-containing wild-type p300 or p500 erbB2 promoter ± reporter (luciferase) constructs, the EBS-mutated p500 m construct, and either an Elf-1 expression vector or vector control (pCDNA3), as indicated. Displayed data represent the mean (+s.d.) of at least two independent transfections performed in duplicate and normalized for transfection eciency for co-expressed b-galactosidase activity, as described in Materials and methods signi®cantly dierent degrees of pHER2-CAT or pTA5-CAT repression (data not shown); and for similar intracellular levels of expressed KK4 fusion protein, the KK4-Ets(DBD) constructs repressed the pHER2-CAT and pTA5-CAT promoters to 42 and 35% of control activity, respectively (Figure 7) . When an inactivating permutation was created in the Ets response element of the pHER2-CAT promoter ± reporter construct and then transfected into MDA-453 cells, a comparable 65% reduction from control pHER2-CAT reporter activity was noted consistent with earlier reports Xing et al., 2000) and indicating that the degree of promoter repression caused by intracellular expression of the KK4-Ets(DBD) fusion protein is nearly equivalent to ablation of the promoter's EBS.
Discussion
Recruitment of an erbB2 transactivating Ets protein may affect proximal promoter architecture and binding by other transcription factors As diagrammed in Figure 1 , the erbB2 proximal promoter contains several closely spaced positiveacting response elements suggesting that some of these are mutually exclusive and not all are involved in the transcriptional overexpression of ErbB2. In particular, steric hindrance imposed by partially overlapping regulatory elements probably prevents the simultaneous promoter recruitment of both Ets factor to the EBS major groove and TATAA box binding protein (TBP) to the minor groove of the adjoining TATAA box element, as we have observed by EMSA when incubating both recombinant Ets protein and TBP to an erbB2 promoter probe (data not shown). Others have characterized a TATAA box footprint when human TBP is incubated alone with an erbB2 promoter probe (Mizuguchi et al., 1994) ; however, results presented here indicate that incubation of the erbB2 promoter with breast cancer nuclear extracts does not produce a TATAA box footprint but rather a characteristic Ets hypersensitivity site whose intensity correlates with the cellular level of ErbB2 expression (Figure 2) . Ets binding to the erbB2 promoter is also probably incompatible with endogenous triplex (H-DNA) formation by the adjacent polypurine(GGA)-polypyrimidine(TCC) mirror repeat element. Earlier studies had indicated that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in triplex binding (Noonberg et al., 1994) , and present results indicate that Ets binding induces severe erbB2 promoter bending (5658) dicult to reconcile with local triplex formation ( Figure 5 ). Likewise, occupation of a CCAAT box binding protein (CBP) to its element may be precluded when either its neighboring upstream Notch-activated RBPJk (R/N*) element is DNA bound or its downstream mirror-repeat element has assumed an H-DNA conformation. Using a panel of antibodies (speci®c for C/EBP, NF-1, or NFY) and EMSA we recently identi®ed NFY as the only endogenously expressed CBP candidate in breast cancer nuclear extracts capable of binding the erbB2 CCAAT box (data not shown). Resolving the speci®c combination of erbB2 promoter regulatory elements and transcription factor binding complexes that direct mRNA initiation at the more upstream 769 bp site, which appears to be preferentially utilized in ErbB2 overexpressing cancer cells relative to the +1 bp site used by low ErbB2 expressing cells (Ishii et al., 1987; Tal et al., 1987; Mizuguchi et al., 1994) , remains a critical issue that can be further addressed by transcript initiation mapping studies using mutated erbB2 reporter constructs.
We have previously shown that some Ets factors capable of binding with very high anity to the erbB2 promoter's EBS (e.g. PU.1/Spi-1) are not expressed in Figure 7 EBS-targeted repression of erbB2 promoter activity by chimeric Ets proteins transfected into ErbB2 overexpressing breast cancer cells. A chimeric Ets construct containing the KRAB repression domain (KK4) fused at the N-terminus of an Ets (PEA3) DNA binding domain, KK4-Ets(DBD), was produced and transiently co-transfected into MDA-453 cells along with one of two dierent Ets-responsive erbB2 promoterreporters, pHER2-CAT and pTA5-CAT. As a positive control for promoter binding speci®city, an AP2 DNA binding domain was similarly fused to KK4 to produce KK4-AP2(DBD), and this construct was compared for its ability to repress the pHER2-CAT promoter ± reporter, which contains a well characterized AP2 response element, with its eect on the truncated pTA5-CAT promoter ± reporter, which lacks any functional AP2 response elements. Negative controls consisted of vector (pCDNA1) alone, the non-DNA binding KK4 expression construct, and KK4 fusion constructs containing reversely oriented Ets and AP2 DBD domains (nonsense expressing sequences), KK4-Ets (control) and KK4-AP2 (control). Cells transfected with KK4-expressing constructs were tested by Western blotting with an anti-KK4 polyclonal to con®rm comparable expression of the 20 kDa KK4 product, 31 kDa KK4-Ets(DBD) and 45 kDa KK4-AP2(DBD) fusion proteins (not shown). As shown, the negative expression controls produced no signi®cant dierences or impact on pHER2-CAT and pTA5-CAT promoter ± reporter activities. The positive speci®city control construct, KK4-AP2(DBD), decreased pHER2-CAT promoter activity to 54% of control without aecting pTA5-CAT promoter ± reporter activity, as expected. In contrast, the KK4-Ets(DBD) construct repressed both pHER2-CAT and pTA5-CAT promoters to 42 and 35% of control activity, respectively normal or malignant mammary epithelium, while others that are abundantly expressed in these tissues (e.g. GABPa) cannot bind to this EBS or directly aect erbB2 promoter activity. Two studies which agreed on the epithelial expression and promoter binding ability of the potential erbB2-regulating Ets candidate, PEA3, came to opposite conclusions about its promoter regulatory role; these were based on transient transfection results which showed stimulation of erbB2 promoter activity in COS cells and repression of erbB2 promoter activity in SK-BR-3 cells (Xing et al., 2000; Hung and Wang, 2000) . One plausible explanation for these contradictory PEA3 conclusions may be found in similar results obtained with the epithelial-speci®c Ets factor, ESX/Elf-3, ®rst shown to stimulate erbB2 promoter activity upon transfection into COS cells and later shown to be a potent acidic transactivator capable of inducing cell-speci®c squelching and repression of both Ets and non-Ets regulated promoters upon transfection into SK-BR-3 cells, presumably due to its TBP sequestering capacity (Chang et al., 1999) . Data presented here now show that transiently transfecting Elf-1 stimulates erbB2 promoter activity in various breast cancer cell lines (including SK-BR-3) in an Ets-speci®c manner and without apparent squelching complications. Endogenous Elf-1 protein present in the nuclear extracts of various breast cancer cells readily binds to the EBS of the erbB2 promoter. However, unlike PEA3 and ESX/Elf-3 which show a positive correlation between their endogenous mRNA and protein levels and co-expressed ErbB2 in tumors and cell lines, Elf-1 shows no correlation between its degree of expression and the co-expression of ErbB2. Thus, it is not yet possible to specify any one endogenous Ets factor as unequivocally associated with erbB2 promoter upregulation in breast cancers overexpressing ErbB2. Furthermore, the availability of several erbB2-regulating Ets candidates supports the possibility that Ets recruitment to the erbB2 EBS is context dependent within dierent breast cancer cells and speci®es both proximal promoter architecture and recruitment of other promoter-regulating factors.
A singular chromatin hypersensitivity site centered over the mirror-repeat element and EBS brought initial focus to this region of the erbB2 proximal promoter . The footprinting studies presented here implicate the binding of an Ets factor to the promoter's EBS in ErbB2 overexpressing breast cancer cells as inducing this chromatin hypersensitive site; and the observation that ErbB2 overexpressing breast cancer cells show a more intense hypersensitive EBS as compared to low ErbB2 expressing cell lines supports conclusions drawn from EBS-mutated erbB2 promoter ± reporter studies for a positive regulatory role played by one or more promoter-bound endogenous Ets factors Xing et al., 2000) . Additionally, nuclease-sensitive regions within eukaryotic promoters frequently contain homopurine-homopyrimidine DNA stretches capable of forming an internal triplex structure, H-DNA, under conditions of supercoiling. An H-DNA conformation within the erbB2 promoter's polypurine(GGA)-polypyrimidine (TCC) mirror-repeat may be expected to have comparable stability to that of its duplexed structure and to exist in the thermodynamically favored isomeric topology of Hr-DNA, in which half of the coding polypurine strand folds back to reverse Hoogsteen bond with the other half of the duplexed mirror-repeat element, leaving as a single stranded D loop the polypyrimidine template strand (Mirkin, 1999) . The present study's S1 digestion and strand-speci®c Southern blotting coupled with single strand-speci®c chemical probing of supercoiled erbB2 promoter (500 bp) construct demonstrates the propensity of the erbB2 promoter's mirror-repeat to spontaneously adopt an Hr-DNA conformation. Con®rmation of this same Hr-DNA promoter topology within the chromatinized erbB2 genome awaits in vitro to in vivo translation of S1 nuclease mapping and chemical probing studies. Based on present evidence, however, in vitro identi®ca-tion of the Hr-DNA structure's D loop as the polypyrimidine template strand suggests that transcriptional blockage might occur in vivo upon RNA-DNA duplexing of the available D loop to the 5' end of a nascent erbB2 transcript (Mirkin, 1999) . This implication of a negative regulatory role for H-DNA formation by the erbB2 promoter's mirror-repeat element is consistent with both the observed enhancement of supercoiled erbB2 promoter activity in low ErbB2 expressing MCF-7 cells when the mirror-repeat element is mutated and unable to form an Hr-DNA structure, and antagonization between Ets protein binding and the erbB2 promoter's ability to engage in triplex formation. Other forms of architectural regulation at this erbB2 Hr-DNA structure might occur by an as yet undiscovered tissue-speci®c Hr-DNA binding protein, such as the nuclear matrix protein found to bind to this mirror-repeat element in low ErbB2 expressing breast cancer cells (Raziuddin et al., 1997) or the single strand binding proteins found to regulate human androgen receptor (ssPyrBF) and fetal hemoglobin (BP8) transcription at similar H-DNA forming promoter elements (Horwitz et al., 1994; Chen et al., 1997b; Guieysse and Praseuth, 1999) .
Future directions and therapeutic translation: transcriptional inhibition of ErbB2 overexpression and EBS-targeted erbB2 promoter silencing
Despite the recent success and acknowledged clinical potential of ErbB2 receptor-targeted therapeutics (Benz and Tripathy, 2000; Krauss et al., 2000) , strategies that transcriptionally inhibit ErbB2 overexpression remain appealing because erbB2 gene and transcript targets per cell are far fewer in number than the expressed ErbB2 protein product, and observed receptor-linked resistance mechanisms now point to the clinical need for additional therapeutic alternatives and combinatorial approaches (Benz and Tripathy, 2000) . Antisense strategies to downregulate ErbB2 expression, either by extracellular treatment with synthetic oligodeoxyribonucleotides or intracellular transfection with antisense-expressing constructs, have proven partially successful at downregulating transcript and protein levels as well as the proliferative activity and viability of ErbB2 overexpressing tumor cells (Colomer et al., 1994; Vaughn et al., 1995; Sacco et al., 1998; Roh et al., 2000) . By exploiting the enzymatic property of ErbB2 transcript-targeted hammerhead ribozymes, intracellularly expressed after adenovirus-mediated tumor cell transduction, this strategy appears to be somewhat more ecient at depleting transcript and receptor levels as well as more eective at tumor growth inhibition when compared to a comparable antisense strategy (Czubayko et al., 1997; Suzuki et al., 2000) . However, neither antisense nor ribozyme strategies to inhibit ErbB2 overexpressing tumors have yet reached clinical trial.
The theoretically more ecient approach of silencing the 2 ± 10-fold ampli®ed copies per tumor cell of the oncogenic erbB2 promoter is also being explored by several labs, but these emerging erbB2 promotertargeted strategies are dependent on a complete understanding of the endogenous erbB2 promoter architecture and the binding components that specify ErbB2 overexpression, as discussed earlier. One such therapeutic strategy, however, E1A-mediated erbB2 promoter repression (mediated by association with the transcriptional co-activator, CBP/p300), has already entered clinical trials based on its empirically observed and indirect ability to repress erbB2 proximal promoter activity (Chen et al., 1997a; Hung and Wang, 2000) . In an early preclinical eort the antirheumatic gold salt, aurothiomalate, which can inhibit DNA binding by AP2 and various other zinc ®nger transcription factors, was shown to downregulate erbB2 promoter activity and endogenous ErbB2 expression in cultured human breast cancer cells (Hollywood and Hurst, 1995) . In a later and more speci®c erbB2 promoter-targeted strategy, a novel polydactyl zinc ®nger protein was ®rst designed that recognized part of the 5'-untranslated region encoded by erbB2 and this was then converted into a transcriptional repressor by N-terminal fusion with a KRAB domain (aa 1 ± 97) from the zinc ®nger protein KOX1; the resulting chimeric repressor produced nearly complete erbB2 promoter repression when cotransfected into low ErbB2 expressing HeLa cells (Beerli et al., 1998) . As well, triplex-forming oligonucleotides speci®cally targeting the erbB2 promoter's mirror-repeat have been extensively tested by several groups with mixed success, in part due to the uncharacterized endogenous promoter architecture at this Hr-DNA forming element (Ebbinghaus et al., 1993 , 1999 , Noonberg et al., 1994 Porumb et al., 1996) . Yet another emerging strategy involves design of erbB2 promoter-speci®c DNA binding pyrrole-imidazole polyamides that prevent erbB2 transcript initiation by inhibiting Ets binding at the promoter's essential EBS (Chiang et al., 2000) .
To further assess the merit of an EBS-targeted strategy in the present study, we generated and expressed Ets fusion proteins to repress transcription within ErbB2 overexpressing cancer cells and in the presence of their endogenous content of erbB2-regulating Ets factors. Similar to the polydactyl zinc ®nger fusion protein described above, these chimeric Ets constructs contain the KK4 KRAB repression domain (aa 1 ± 160) fused to the homologous Ets domain (DBD) of PEA3 or ESX/Elf-3. Because of the short time frame of these transient co-transfection assays (48 ± 72 h), complete inhibition of erbB2 promoter ± reporter activity was not expected by these chimeric Ets repressors; and results showed that their transient intracellular expression achieved sucient levels to compete with endogenous Ets proteins within ErbB2 overexpressing MDA-453 cells and inhibit erbB2 promoter activity to a degree equivalent to that produced by mutation of the promoter's EBS.
In sum, additional in vitro studies are necessary to assess the erbB2 promoter-silencing potential of chimeric Ets repressors which, like all the other erbB2 promoter-targeting and transcription inhibiting strategies currently under preclinical development, face intracellular and intranuclear delivery and tracking challenges prior to their in vivo assessment and utilization. Nonetheless, these novel promoter-targeting reagents provide us with a critical set of experimental tools for further exploration into the structural and functional dierences that characterize the overexpressing erbB2 promoter.
Materials and methods

Cell lines and plasmids
Cell lines were cultured with 10% fetal calf serum (FCS) in DMEM (MCF-7, MCF7/HER2-18, MCF-10A, HBL-100), McCoys (SKBR-3), RPMI (ZR75-1, BT-474) or Leibovitz's L-15 medium (MDA-MB-231, MDA-MB-453, MDA-MB-468), as recommended by the American Type Culture Collection (ATCC). All cells were harvested for preparation of nuclear extracts at 80% con¯uency. Jurkat and Raji cells were cultured in RPMI with 5% FCS. The ln2 erbB2 genomic clone (Tal et al., 1987) was used to generate the RO6 erbB2 promoter plasmid and a similar AfIII/NcoI (7547/+149) promoter-chloramphenicol acetyl transferase (CAT) reporter construct containing 547 bp of the human ErbB2 promoter sequence without or with a mutated EBS (pHER2-CAT, pHER2m-CAT), as well as truncated versions of this promoter construct containing three repeats of the 31 bp TA5 element containing either normal or mutated EBS (p3TA5-CAT, p3TA5P-CAT). For luciferase reporter gene constructs, 300 bp (p300-LUC) and 500 bp (p500-LUC) promoter fragments from RO6 were restricted (KpnI, BgIII) and inserted into PGL3 (Promega Corp. Ltd.) luciferase vectors, as indicated. The b-galactosidase expressing plasmid pCH110 (Pharmacia) was used as a control for monitoring transfection eciency. The full-length coding region of Elf-1 cDNA was obtained from CB Thompson and J Leiden (University of Chicago) and inserted into the pCDNA3 (Invitrogen) expression vector. Chimeric Ets repression constructs were generated in the pCDNA1 expression vector (Invitrogen) using the Ets domain from either PEA3 or ESX/ Elf-3 C-terminally fused to a 160 amino acid human KOX1/ KRAB (Kruppel-associated box)-containing repression domain derived from the pCB6+ plasmid (Margolin et al., 1994) .
Ets-induced erbB2 promoter bending and DNase-I footprinting
Footprinting and bending analyses were performed with fulllength and truncated Ets proteins (PU.1 and ESX/Elf-3) previously shown to bind to linearized erbB2 promoter probes by electrophoretic mobility shift assay (EMSA). The series of N-terminally deleted recombinant ESX/Elf-3 protein fragments were produced and puri®ed as reported earlier (Chang et al., 1999) . Ets-induced promoter bending was measured by the circular permutation assay (Thompson and Landy, 1988; Wechsler and Dang, 1992 ) using a 16 bp erbB2 promoter fragment (coding strand: TGCTTGAGGAAGTA-TA) containing the EBS (GAGGAA) cloned into pBend2 (obtained from D Wechsler, University of Michigan) to produce circularly permutated bending fragments (BamHI, BgIII, and StuI) of 136 bp. Gel electrophoresis was performed in 0.56 TBE on 5% (29 : 1) polyacrylaminde gels. As previously established (Thompson and Landy, 1988; Verrijzer et al., 1991) , the bending angle (a) is de®ned as the angle by which a segment of the DNA departs from linearity and is calculated using the equation cos(a/2)=m m / m E , where m m is the gel mobility with the protein bound centrally (to the StuI fragment) and m E is the gel mobility with the protein bound at an end (to the BamHI or BgIII fragment). While no anomalous migration was observed for the free erbB2 promoter-containing probe fragments, electrophoretic mobility anomolies in protein-DNA complexes can be observed due to changes in protein shape or rigidity, independent of protein-induced DNA structural distortions; and to rule out such anomolies, a ligase-mediated nonelectrophoretic cyclization assay was also employed (Verrijzer et al., 1991; McCormick et al., 1996) . This assay is based on the observation that if a protein bound to a linear DNA fragment actually bends the DNA, the end-to-end distance will decrease and, in the presence of ligase, the probability of ring closure can be shown to increase. For DNase-I footprinting, performed as previously reported Benz et al., 1997) , SmaI restricted ln2 generated a 537 bp erbB2 promoter fragment which was then labeled with T4 polynucleotide kinase and (g-32P)ATP, cut with BssHII to produce a 125 bp probe labeled on the non-coding strand at the downstream SmaI site. DNase-I cleavage was performed in the absence or presence of recombinant Ets protein (fulllength or truncated PU.1) or Dignam-type nuclear extracts (see EMSA procedure, below) from the indicated cell line, with or without the addition of competing oligonucleotides. The DNA pellets were dried and resuspended in formamidecontaining sequencing loading buer, and the suspensions heated and loaded onto 6% polyacrilamide-8 M urea sequencing gels. The unlabeled oligonucleotide competitors, wild type TA5 and mutated variants of this promoter sequence as previously described , were added in 50-fold molar excess to demonstrate EBS speci®city for the observed footprint and hypersensitivity site. S1 nuclease mapping and chemical probing of erbB2 promoter structure S1 nuclease mapping was based on modi®cation of earlier described techniques showing rapid non-random initial S1 nuclease single-strand cutting in non-B DNA structures prior to slower phase conversion to linear DNA after cleavage of the strand opposite the initial nick (Panayotatos and Wells, 1981; Htun and Dahlberg, 1989) . DNA strand preference with the initial nick of a supercoiled plasmid can be shown after short (20 s) S1 digestion followed by restriction of the relaxed circular DNA, separation by denaturating gel electrophoresis, blotting and strand-speci®c probing. Supercoiled RO6 plasmid samples were digested with 1.6 units of S1 endonuclease/mg of DNA in 30 mM sodium acetate (pH 4.6), 1 mM zinc acetate, and 5% glycerol for 20 s at room temperature before stopping the reactions and extracting DNA with phenol:chloroform:isoamyl alcohol (25 : 24 : 1). In some cases, the DNA samples were further digested with restriction enzymes (Pst1 and/or HindIII) before boiling in a denaturing loading buer. DNA samples were then electrophoresed into denaturing agarose (1%) or acrylamide-urea (7%, 8 M) gels, blotted onto a nylon membrane, and hybridized to radiolabeled strand-speci®c probes generated by end-labeling of single stranded oligonucleotides with T4 polynucleotide kinase. Promoter probes used included those speci®c for single strand fragments downstream of the EBS, the region between the polypurine-polypyrimidine repeat and the upstream Pst1 site, and the most upstream portion of the polypurine-polypyrimidine repeat. For high resolution chemical probing of supercoiled RO6 plasmid nucleotides not involved in either duplex or triplex formation, chemical modi®cation was performed using osmium tetroxide (OT) and diethylpyrocarbonate (DEPC), which are speci®c for accessible T pyrimidines and A or G purines, respectively (Htun and Dahlberg, 1988) . For OT reactivity, 10 mg DNA was treated with 2 mM OT in pH 4.5 buer (20 mM sodium acetate, pH 4.5, 4 mM magnesium chloride, 100 mM sodium chloride, 2 mM 2,2'-bipyridine) or pH 7.8 buer (10 mM Tris HCl, pH 7.8, 1 mM EDTA, 4 mM magnesium chloride, 100 mM sodium chloride) at 258C for 20 min. For DEPC reactivity, 10 mg DNA was treated with 2 mL DEPC in pH 4.5 or 7.8 buers at 208C for 20 min with agitation at 5 min intervals. Reactions were terminated by three ethanol precipitations. Chemically modi®ed samples were then treated with restriction enzymes and alkaline phosphatase, and then radiolabeled on one terminus of the selective DNA strands using either T4 polynucleotide kinase or Klenow fragment of E. coli DNA polymerase I with [ 32 P]deoxyribonucleotide triphosphates. Further treatment with 10% piperidine was performed at 908C for 40 min, and the cleaved DNA samples were then lyophilized. A separate sequencing reaction was performed by the dideoxy chain-termination method to generate a single bp resolving ladder. The cleaved samples were run alongside the sequencing ladder on denaturing 6% sequencing gels to localize the chemical sensitive sites.
Transient transfection assays
Plasmids used for transfection assays were prepared using plasmid Maxi Kits from Qiagen. Transient transfection experiments were carried out with Lipofectamine reagent (Gibco BRL) according to the manufacturer's recommendations. Brie¯y, subcon¯uent cells in 60 mm diameter plates were transfected with a total of 4 mg DNA consisting of 0.5 mg of reporter plasmid, 2.5 mg of expression plasmid and 1 mg of the internal control plasmid. Following transfection (48 h), cells were harvested and extracts prepared for CAT or luciferase assays as previously described (Chang et al., , 1999 . For each experiment, at least three independent transfections were performed and results are expressed as the mean+s.e.mean reporter activity in relative units. Additionally, the intracellular expression level was veri®ed after transient transfection of all expression constructs by Western blotting.
Northerns, Westerns and electrophoretic mobility shifts assays (EMSA)
For Northern blotting, total cell RNA (10 mg/sample lane) was electrophoresed into 1% agarose-formaldehyde gels and transferred onto membranes that were then hybridized with 32 P-probes labeled, washed and autoradiographed as previously described . For Western blotting, whole-cell or nuclear extracts were boiled in sample loading buer (1% SDS, 20% glycerol, 100 mM DTT, 50 mM Tris pH 6.8) and then electrophoresed into 9% sodium dodecyl sulfate polyacrylamide gels (SDS ± PAGE) and transferred onto membranes (Immobilon-P, Millipore) by electroblotting at room temperature (Hoeer, 250 mA, 1.5 h). Protein-bound membranes were blocked in PBS containing 5% dried milk and 0.1% Tween 20, incubated in the same buer with antiElf-1 (Santa Cruz Biotechnology) or anti-KK4 (F Rauscher) antibodies, and then incubated with a secondary IgG antibody conjugated to horseradish peroxidase (Sigma). Protein bands were visualized using the SuperSignal chemiluminescent substrate (Pierce). For EMSA, Dignamtype nuclear extracts were prepared; brie¯y, after lysis of cells with NP-40, nuclear proteins were extracted with buer C (0.4 M KCl, 20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) followed by high speed centrifugation at 30 000 r.p.m. for 60 min at 48C. All buers included the following protease inhibitors, PMSF (0.5 mM), aprotinin (5 mg/ml), leupeptin (2.5 mg/ml) and chymostatin (100 ng/ml). Protein content was determined using the Bio-Rad protein assay.
Extract incubation was performed at room temperature for 30 min with approximately 15 fmol of 32 P-dATP-kinased speci®c double stranded DNA oligodeoxynucleotide probe in buer (20 mM HEPES, pH 7.9, 1 mM DTT, 0.2 mM EDTA, 10% glycerol, 350 ng poly(dI-dC), 0.33 mg/ml BSA and 0.03 ng/ml tRNA) was incubated with 4 mg of nuclear extract in a ®nal volume of 10 ml. Samples were loaded onto 4% non-denaturing polyacrylamide gels in 0.256 TBE and run at 200 V at 48C for 2 ± 3 h; after drying, gels were autoradiographed at 7708C.
Immunohistochemical analysis of tumor samples for Elf-1 expression
Formalin-®xed and paran embedded breast tumor sections (4 micron) previously characterized by immunohistochemistry for ErbB2 receptor status were deparanized, washed in PBS, and adjacent sections incubated with Elf-1 speci®c primary antibody (Santa-Cruz Biotechnology) overnight at 48C. Primary antibody dilution was optimized against a panel of ®xed and paran embedded breast cancer cell pellets to achieve speci®c staining (% immunoreactive cells) that correlated with expression of these proteins as determined by Western blotting total cell extracts with the same antibody. After PBS washing of sections incubated with the primary antibody, slides were incubated with avidin-linked secondary antibody and streptavidin peroxidase (DAKO). The immunoperoxidase reaction was developed with 3'3-diaminobenzidine, cells counterstained with hematoxylin, and immunohistochemical scoring performed independently by two dierent pathologists.
